MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1212/nxi.0000000000000664

Медицинская библиотека · Neurology(R) neuroimmunology & neuroinflammation · 2020

Tick-borne encephalitis vaccination in multiple sclerosis: A prospective, multicenter study.

Winkelmann Alexander, Metze Christoph, Frimmel Silvius, Reisinger Emil C, Zettl Uwe K, Loebermann Micha

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

To assess the changes in disease activity after tick-borne encephalitis (TBE) vaccination in patients with multiple sclerosis (MS) on a variety of disease-modifying drugs and to assess the immunogenicity, safety, and clinical tolerability of the vaccine in this patient group.

METHODS

We conducted a prospective, multicenter, nonrandomized observational study. We enrolled 20 patients with MS receiving TBE vaccination who had been on disease-modifying treatment (DMT) for at least 6 months. Serum samples were obtained before and after 4 weeks of vaccination to determine the specific TBE antibody response. MS disease activity (Expanded Disability Status Scale and relapse rates) was evaluated for 1 year after immunization. Local and systemic adverse events were registered.

RESULTS

In 20 subjects with TBE vaccination, the annualized relapse rate decreased from 0.65 in the year before vaccination to 0.21 in the following year. Expanded Disability Status Scale remained stable during the 2-year period before vaccination and 1 year after vaccination (range: 1.50-1.97). The geometric mean titer (GMT) increased from 169 Vienna units per milliliter (VIEU/mL) to 719 VIEU/mL 4 weeks after vaccination (p = 0.001), and 77.8% had protective antibody titers after vaccination. In 9 patients treated with beta interferons, GMT increased from 181 VIEU/mL to 690 VIEU/mL (p = 0.018). Three subjects treated with glatiramer acetate developed a 2- to 9.6-fold increase. Patients treated with fingolimod developed the lowest increase in antibody titer.

CONCLUSION

TBE vaccination showed good tolerability and was safe in patients with MS. MS disease activity was not increased, and annualized relapse rates decreased after vaccination. Vaccine response differs according to the underlying DMT.

TRIAL REGISTRATION: ClinicalTrials.gov, clinicaltrials.gov, Identifier: NCT02275741.

Для цитирования: Winkelmann Alexander, Metze Christoph, Frimmel Silvius, Reisinger Emil C, Zettl Uwe K, Loebermann Micha. Tick-borne encephalitis vaccination in multiple sclerosis: A prospective, multicenter study.. Neurology(R) neuroimmunology & neuroinflammation. 2020. DOI: 10.1212/nxi.0000000000000664.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.